Cancers, Vol. 13, Pages 5239: Future Perspective of Chemotherapy and Pharmacotherapy in Thymic Carcinoma

Cancers, Vol. 13, Pages 5239: Future Perspective of Chemotherapy and Pharmacotherapy in Thymic Carcinoma Cancers doi: 10.3390/cancers13205239 Authors: Rui Kitadai Yusuke Okuma Thymic carcinoma is a rare cancer that arises from thymic epithelial cells. Its nature and pathology differ from that of benign thymoma, presenting a poorer prognosis. If surgically resectable, surgery alone or surgery followed by chemoradiotherapy or radiotherapy is recommended by the National Comprehensive Cancer Network Guidelines. Metastatic and refractory thymic carcinomas require systemic pharmacotherapy. Combined carboplatin and paclitaxel, and cisplatin and anthracycline-based regimens have been shown a fair response rate and survival to provide a de facto standard of care when compared with other drugs employed as first-line chemotherapy. Cytotoxic agents have been pivotal for treating thymic carcinoma, as little is known regarding its tumorigenesis. In addition, genetic alterations, including driver mutations, which play an important role in treatments, have not yet been discovered. However, molecular pathways and biomarker studies assessing thymic epithelial tumors have been reported recently, resulting in the development of new agents, such as molecular targeted agents and immune checkpoint inhibitors. As treatment options are currently limited and the prognosis remains poor in metastases and recurrent thymic carcinoma, genetic alterations need to be assessed. In the present review...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research